Medivation and Astellas Provide Additional Support to Metastatic Prostate
Cancer Patients Through Donations to Independent Non-Profit
Patient Assistance Organization
SAN FRANCISCO, CA and NORTHBROOK, IL -- (Marketwire) -- 02/25/13 --
Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma US, Inc., a U.S.
subsidiary of Tokyo-based Astellas Pharma Inc. (TSE: 4503), announced
that the companies are providing additional support to the Chronic
Disease Fund (CDF). CDF uses charitable donations to help eligible
men with metastatic castration resistant prostate cancer that need
financial assistance paying their out-of-pocket expenses, including
co-pays or co-insurance. CDF is an independent, non-profit
organization that provides financial assistance to help eligible
patients obtain prescription medications. Independent of Astellas and
Medivation, CDF determines how to distribute donations and evaluate
"Astellas and Medivation are committed to helping patients access
medicines their physicians believe are necessary. Organizations like
CDF provide an invaluable resource to patients in need and we applaud
their efforts," said Mark Reisenauer, Vice President, Astellas
"We are proud to support non-profit charitable organizations, such as
the CDF, that are striving to provide the greatest level of access,
care and assistance to patients to help them obtain the medicines
that they need," said Melissa Abel, Vice President at Medivation,
Information about programs established to help patients gain access
to approved medications can be found at www.astellasaccess.com.
Medivation, Inc. is a biopharmaceutical company
focused on the rapid development of novel therapies to treat serious
diseases for which there are limited treatment options. Medivation
aims to transform the treatment of these diseases and offer hope to
critically ill patients and their families. For more information,
please visit us at www.medivation.com.
Astellas Pharma US, Inc., located in Northbrook,
Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc.
Astellas is a pharmaceutical company dedicated to improving the
health of people around the world through the provision of innovative
and reliable pharmaceutical products. The organization is committed
to becoming a global category leader in oncology, and has several
oncology products on the market and compounds in development.
Astellas is proud to be an award recipient of the CEO Gold Standard
Accreditation from the CEO Roundtable on Cancer. For more information
on Astellas Pharma Inc., please visit our website at www.astellas.us.
Chief Business & Financial Officer
Senior Director, Investor Relations
Sam Brown, Inc (media for both companies)
Press spacebar to pause and continue. Press esc to stop.